MétaCan
Menu
Back to cohort

Abstract P6-11-05: ANG4043, a brain-penetrant anti-HER2 mAb increases survival in mice bearing intracranial BT-474 breast tumor cells

2013· article· en· W2049657582 on OpenAlexaff
JE Lachowicz, Michel Demeule, Anthony Régina, Emilie Houle, Sasmita Tripathy, J. Castaigne

Bibliographic record

VenueCancer Research · 2013
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Research Studies
Canadian institutionsAngiochem (Canada)
Fundersnot available
KeywordsTranscytosisBrain tumorIn vivoCancer researchReceptorMedicineMonoclonal antibodyPharmacologyInternal medicineBiologyAntibodyPathologyImmunology

Abstract

fetched live from OpenAlex

Abstract Background: Treatment options for metastatic brain tumors originating from HER2-positive breast disease are limited due to the inability of most anti-tumor agents to enter the brain. While the selectively permeable blood-brain barrier (BBB) restricts access of therapeutics such as mAbs to the brain, transcytosis of hormones, nutrients, and other homeostatic modulators is mediated by transporters and endogenous receptors such as the low density lipoprotein receptor-related protein 1 (LRP1). We have created a family of peptides (Angiopeps) that are recognized by LRP1 and enter the brain via receptor-mediated transcytosis. Using these proprietary Angiopeps, we have created novel, brain-penetrant Peptide-Drug Conjugates. An iterative process of linker selection and reaction condition optimization led to the discovery of ANG4043, a conjugate of the peptide Angiopep-2 (An2) and an anti-HER2 mAb similar to trastuzimab. This brain-penetrant An2-mAb conjugate, which displays HER2 binding affinity and in vitro anti-proliferative properties similar to that of the native mAb, was tested in a murine model of breast tumor brain metastases. Methods: Athymic nude mice were stereotactically implanted 1.5 mm anterior and 2.5 mm lateral to bregma with 1×106 BT-474 cells twelve days prior to initiation of drug treatment. Body weight and morbidity/mortality were monitored daily. Separate groups of mice received mAbs that were labeled with the fluorescent probe Cyto-750 to allow for near infrared in vivo imaging. Results: Median survival in the control group was 45 days, compared with 68 days and 80 days for the 5 mg/kg (p = 0.0005) and 15 mg/kg (p = 0.0003) groups, respectively, demonstrating a 51% and 78% improvement over the control group. In addition, a greater degree of fluorescence was observed in intracranial BT-474 brain tumors in the ANG4043 group compared to the native anti-HER2 mAb group. Conclusions: These data demonstrate that ANG4043 reaches its target in brain tumors and increases survival in a mouse HER2-positive intracranial tumor model. These results extend the validation of An2 conjugation beyond small molecules and peptides to include larger molecules such as therapeutic mAbs for development of new brain-penetrant anti-tumor therapeutics. We intend to progress this program to clinical stages both as monotherapy and in combination with ANG1005, the An2-paclitaxel conjugate that has shown encouraging results in clinical studies with primary brain tumors and breast cancer brain metastases. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-11-05.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.713
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.383
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicLung Cancer Research StudiesFrench-language works237,207